Your session is about to expire
← Back to Search
Avelumab + Cetuximab + Palbociclib for Head and Neck Cancer
Study Summary
This trial is testing if Avelumab, Cetuximab, and Palbociclib can help treat people with solid tumors that have spread (metastasized).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In what treatments is Avelumab routinely employed?
"Avelumab is a standard intervention for merkel cell carcinoma. Additionally, it has been employed to reduce the severity of breast cancer when complemented with radiation and pharmacotherapy."
Has Avelumab obtained regulatory acceptance from the FDA?
"Given the limited clinical data supporting both safety and efficacy, our team at Power gave Avelumab a score of 1 on its risk assessment scale."
What is the quota of participants involved with this research?
"Unfortunately, this clinical trial is not currently recruiting participants. It was initially posted on June 6th 2018 and last amended in February 16th 2022. However, there are 2675 trials searching for patients with malignant neoplasms and 346 studies enlisting Avelumab users that you may find suitable to apply for."
Is there still room for participation in this experiment?
"According to clinicaltrials.gov, this medical trial has concluded its search for prospective patients. The study was first created on June 6th 2018 and last updated on February 16th 2022; however, there are over 3 thousand other trails that are still open for enrollment at the moment."
What other experiments have been conducted using Avelumab as a treatment?
"Presently, there are 54 Phase 3 trials and a grand total of 346 clinical studies related to Avelumab. Mostly based in Dresden, Arizona, these research projects also involve 15172 different medical centres."
Share this study with friends
Copy Link
Messenger